BCL2L2 Is A Valid Target Of MiR-145 In Breast Cancer

It has been reported that the expression of miR-145 is down-regulated in breast cancer tissues. It plays a regulatory role as a tumor suppressor gene. miR-145 inhibits tumor angiogenesis, and plays a role in pro-apoptotic pathway. Expression of miR-145 is induced transcriptionally by p53 through interaction of p53 response element in the promoter region of miR-145. Due to early manifestation of altered miR-145 expression in breast cancer, this miRNA may have a clinical diagnostic potential as a novel biomarker for early cancer detection. In the inhibition of tumor angiogenesis, it regulates the vascular endothelial growth factor VEGF, but the mechanism of pro-apoptotic is unclear. We found the expression of BCL2L2 and miR-145 showed a significant negative correlation in breast cancer, and the upregulation of BCL2L2 can reduce apoptosis. After using software to analyze, we got that BCL2L2 may be the target of miR-145. Then we transfected miR-145 oligonucleotide and developed a cell line which can express miR-145 stably. The results verified BCL2L2 is the target of miR-145 expression. Our research suggested that miR-145 and BCL2L2 could be used as a potential therapeutic target in breast cancer.